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Abstract
Leakage of the blood–brain barrier (BBB) is a common pathological feature in multiple sclerosis (MS). Following a
breach of the BBB, albumin, the most abundant protein in plasma, gains access to CNS tissue where it is exposed
to an inflammatory milieu and tissue damage, e.g., demyelination. Once in the CNS, albumin can participate in
protective mechanisms. For example, due to its high concentration and molecular properties, albumin becomes a
target for oxidation and nitration reactions. Furthermore, albumin binds metals and heme thereby limiting their
ability to produce reactive oxygen and reactive nitrogen species. Albumin also has the potential to worsen disease.
Similar to pathogenic processes that occur during epilepsy, extravasated albumin could induce the expression of
proinflammatory cytokines and affect the ability of astrocytes to maintain potassium homeostasis thereby possibly
making neurons more vulnerable to glutamate exicitotoxicity, which is thought to be a pathogenic mechanism in
MS. The albumin quotient, albumin in cerebrospinal fluid (CSF)/albumin in serum, is used as a measure of blood-
CSF barrier dysfunction in MS, but it may be inaccurate since albumin levels in the CSF can be influenced by
multiple factors including: 1) albumin becomes proteolytically cleaved during disease, 2) extravasated albumin is
taken up by macrophages, microglia, and astrocytes, and 3) the location of BBB damage affects the entry of
extravasated albumin into ventricular CSF. A discussion of the roles that albumin performs during MS is put forth.
Keywords: Albumin, Albumin quotient, Blood–brain barrier, Cerebrospinal fluid, Experimental autoimmune
encephalomyelitis, Macrophages, Multiple sclerosis, Reactive nitrogen species, Reactive oxygen species
Background
Multiple sclerosis (MS) is believed to result from an
underlying autoimmune mechanism that leads to the de-
velopment of central nervous system (CNS) lesions that
eventually cause sensory and motor symptoms [1, 2].
The majority of patients experience a relapsing remitting
type of MS (RRMS), but over time the condition
frequently transitions into a progressive form of disease
[1, 2]. Active demyelinating lesions can result from pro-
inflammatory immune cells migrating across the vascu-
lature into the CNS, and this process is affiliated with a
breakdown of the blood–brain barrier (BBB) [3–5]. Be-
sides this association with immune cells, BBB leakage
can result in the extravasation of plasma components
that cross damaged vessels and enter the CNS. Perivas-
cular immune cells and vascular leakage occur in both
acute and chronic MS lesions [6], and damage to the
BBB may be relatively persistent since vascular changes
can be present without concurrent inflammatory cells,
e.g., after their departure, and plasma proteins can be
present in older, inactive lesions [7, 8]. Vascular leakage
can also occur in normal appearing white matter [9–12],
and although BBB disruption usually occurs in the devel-
opment of a new lesion, evidence suggests that it might
also arise following neurodegeneration in MS [11, 13].
Serum albumin represents ~50 % of the proteins in
plasma where it has a half-life of ~15–20 days [14, 15].
Serum albumin is a ~66.4 kDa, heart shaped protein that
has a variety of functions including being the primary
plasma component affecting oncotic pressure, transport-
ing fatty acids, carrying some hormones, influencing
drug pharmacokinetics, binding metals and heme, and
acting as an anti-oxidant [14, 15]. Given its high concen-
tration in the plasma, albumin would be expected to ac-
cess CNS tissue following the breakdown of the BBB
that occurs during MS. Once in the CNS, evidence sug-
gests that albumin is not an inert bystander, but rather is
positioned to impact the disease course given its relative
abundance, its molecular properties, and the reoccurring
and/or chronic nature of BBB disruption during disease.
In this review, a discussion is put forth about various
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protective and pathogenic mechanisms of albumin rela-
tive to MS.
Review
A compromised BBB is a common occurrence in MS
MRI detection of gadolinium (Gd) enhancing lesions is
one measure used for the diagnosis of MS and for moni-
toring disease activity [16, 17]. Gd does not enter the
brain when there is an intact BBB, but when there is a
breach in the BBB, it appears as a local enhancement.
Gd-enhancing lesions occur most commonly in RRMS
and secondary progressive MS (SPMS), but can also
occur in benign MS, clinically isolated syndrome,
pediatric MS, and primary progressive MS (PPMS)
(more commonly, enhancing lesions occur earlier in the
course of PPMS), and enhancements are usually consid-
ered a marker of active lesions [18–23]. Lesions can have
different appearances, with nodular or uniform Gd en-
hancements representing new lesions associated with
BBB leakage while ring or arc enhancements suggest
older lesions [24, 25]. Based on numerous Gd studies,
the breakdown of the BBB is relatively common occur-
rence during MS, and a triple dose of Gd may increase
the ability to detect lesions [18, 19, 26] with one study
revealing an average of 5.17 (median 3.38) enhancing le-
sions per month per patient (37 RRMS, 3 SPMS) with
an average of 3.37 (median 2.5) of the lesions being new
enhancements per month per patient when using a delay
of 20 min for imaging after the administration of a triple
dose of Gd [27].
BBB damage in MS results in excess albumin gaining
access to the CNS
BBB leakage results in the extravasation of leukocytes,
some red blood cells (RBCs), and plasma proteins into
the CNS in both experimental autoimmune encephalo-
myelitis (EAE) [28–31], an animal model of MS, and MS
tissue [32–35]. Since albumin is the predominant protein
in plasma, it would be expected to be among the
proteins that gain access to the CNS. For instance,
proteomic [30, 36], immunohistochemical [37–40], im-
munoblotting [41], Evan’s blue labeled albumin [42],
CSF [43, 44], and radiolabeled albumin [45] studies in
EAE subjects revealed that albumin enters the CNS dur-
ing disease. Albumin extravasation precedes both cellu-
lar inflammation and clinical signs, and it occurs initially
around vessels, i.e., perivascular space in subpia, and
then spreads diffusely into the CNS [38].
In human MS tissue, albumin was found widely dis-
persed in the CNS in immunohistochemical studies of
mostly chronic MS cases [46] and inactive plaques [7],
and it was revealed by proteomics studies in some
chronic plaques/lesions [35, 47]. It is somewhat surpris-
ing that albumin has not been detected or described
more frequently in active MS plaques, especially since a
low dose of gadofosveset trisodium, a Gd compound that
binds albumin reversibly, revealed more enhancements,
albeit at a 4 h time point, compared to gadoterate
meglumine (only < 4 % is bound to plasma proteins in
vitro [48]), at a more standard 4 min time point [49].
Some possible reasons why albumin has not been de-
tected or described more frequently in active plaques are
as follows. In contrast to fibrinogen, which is more dis-
cretely localized around leaky vessels and readily de-
tected in active plaques [46, 50, 51], the distribution of
albumin appears to be more widespread following BBB
leakage [7, 40, 46] which could make it more difficult to
detect by immunohistochemistry. Additionally, albumin
appears to be cleared relatively quickly from the CNS
following extravasation [40]. Albumin that was labeled
with gold, for detection via electron microscopy, has
been shown to be rapidly taken up by subarachnoidal
macrophages [52], which is relevant since macrophages
are a substantial component of active lesions, but less so
in inactive plaques [53–55], which interestingly have
more detectable albumin [7]. Albumin is also proteo-
lytically cleaved during acute phases of RRMS [56],
which could make it more difficult to detect by
immunohistochemistry.
CSF albumin levels or the albumin quotient (albumin
in CSF/albumin in serum) were elevated in ~12–23 %
of MS cases [57–62]. An elevated level of albumin in
the CSF, or an elevated albumin quotient, is thought to
be a measure of blood-CSF dysfunction in MS [63], and
it has been used as an indicator of BBB permeability
[58, 60, 62]. The albumin quotient is less sensitive than
Gd MRI for detecting BBB disruption especially in
supraspinal lesions [64], and the albumin quotient is
sensitive to the subject’s age [65].
Detection of an elevation of albumin in CSF would be
expected to be dependent on the timing and location of
BBB leakage. Albumin rapidly diffuses through the rat
brain with a disappearance half-life of ~12 h [66]. After
infusion into the caudate nucleus of the rat, only a rela-
tively small percentage of the infused albumin ended up
in the CSF at the cisterna magna [66] indicating that
albumin can exit the CNS by a route(s) other than
through the ventricular system [64, 66]. Indeed, follow-
ing an intracerebral injection of ovalbumin in mice,
some digestion products found their way to the cervical
lymph node [67]. Although caution about extrapolation
of these results is warranted, since ovalbumin is antigen-
ically different than mouse albumin, ovalbumin products
were observed in the lymph node at 2, 4, and 8 h, and
7 days, following an intracerebral injection [67]. A
small percentage of the digestion products remained in
the CNS, i.e., in CD11B/MAC-1+ cells (monocytes),
over long periods, e.g., 4 weeks after injection, but
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these were largely present around the injection site
[67]. In addition to different exit routes, it is likely that
a change in CSF albumin levels during MS is sensitive
to the location of the BBB leakage with spinal lesions
and possibly circumventricular lesions potentially giv-
ing rise to the greatest elevation [64]. It is also relevant
to note that CSF albumin levels are dependent on the
rate of albumin influx from multiple sources (e.g.,
transport from blood to CSF in the choroid plexus,
BBB leakage, and possibly synthesis within the CNS) as
well as the rate of efflux (e.g., turnover or flow of CSF).
In normal individuals, the major source of CSF albu-
min is its transport from the blood, via binding glyco-
protein receptors on epithelial cells in the choroid
plexus, and subsequent transfer into the ventricular
CSF [68]. In MS, changes in albumin transfer through
the choroid plexus, BBB leakage, and an increased
CNS synthesis of albumin could all affect the CSF albu-
min concentration.
The volume of CSF is renewed rapidly in the 3 month
(11 times/day) and 19 month (10.8 times/day) rat, and
more slowly in the 30 month rat (3 times/day) [69]. In
the human, CSF is renewed ~4 times/day [69]. The
clearance of albumin in the CSF is relatively fast, e.g., in
the mouse, albumin administered to the CSF resulted in
its rapid clearance, e.g., only ~6 % remained in the CSF
at 1 h [70]. During disease, the rate of albumin turn-
over/clearance could be altered. The rate of CSF flow
through the aqueduct of Sylvius is decreased in MS pa-
tients [71], and a decreased flow could alter albumin
concentrations [72], e.g., if the rate of albumin influx
was constant but flow decreased, then the albumin con-
centration could increase.
Additionally, albumin catabolism could affect its
concentration in CSF. Albumin is rapidly sequestered
by subarachnoidal macrophages [52] and it can be
taken up by astrocytes, microglia and neurons [73–76].
Furthermore, albumin fragments were found in the
CSF of RRMS subjects during an acute phase, and
these were differentially observed compared to CSF
from control and Leber hereditary optic neuropathy
subjects [56]. It has been suggested that albumin frag-
mentation is due to protease action by infiltrating
immune cells [56]. Cytotoxic lymphocytes and macro-
phages produce proteases [77, 78], that in theory could
act on albumin [56], but albumin fragmentation has
been observed in the CSF from hydrocephalus [79],
which results in a different inflammatory profile than
MS. Data from a study on bronchoalveolar lavage fluid
suggested that matrix metalloproteinase 3 (MMP-3)
was responsible for digesting albumin, although other
proteases may have also been involved in the fragmen-
tation [80]. MMP-3 plasma levels are elevated in MS
compared to control subjects [81] and MMP-3 levels
in serum are increased during a relapse compared to
remission [82]. MMP-3 is produced by a variety of
CNS cells, e.g., microglia/macrophages, pericytes, as-
trocytes, endothelial cells, and ischemic neurons [83–
85], and in MS MMP-3 expression has been observed
in microglia/macrophages, astrocytes, and microves-
sels [86]. It is likely that multiple proteases act on albu-
min during MS, but independent of the cause of
albumin fragmentation, the detection of albumin in
CSF (or serum) by electrophoresis could miss these
fragments resulting in an underrepresentation of the
amount of albumin in CSF from MS subjects. Thus, al-
bumin levels might be elevated in a greater percentage
of MS patients if fragmented albumin was detected by
the assay.
Given that multiple factors can influence CSF albumin
levels, an assay measuring CSF albumin levels would be
expected to be an imprecise way to assess BBB leakage,
or blood-CSF dysfunction, in MS. A summary of influ-
encing factors include: BBB damage can occur anywhere
in the CNS and the location of BBB leakage can affect
the entry of albumin into the ventricular system; the rate
of albumin or CSF transport or production may be al-
tered during disease; albumin leaked into the CNS can
exit by means other than into the ventricular system; the
timing of CSF collection may not exactly coincide with
the maximal peak of BBB leakage; extravasated albumin
can be catabolized by immune or CNS cells; and the
assay likely misses albumin that has been digested. Thus,
the determination that ~12–23 % of MS cases have an
elevated CSF albumin or albumin quotient, and there-
fore a leaky BBB [57–62], could be inaccurate. If the al-
bumin quotient is flawed, then this has the potential to
impact the CSF IgG index, which is a commonly used as
a measure of IgG production within the CNS, since the
index represents the ratio of CSF IgG to CSF albumin
divided by the ratio of serum IgG to serum albumin.
However, at present there is little data that directly ad-
dresses whether the albumin quotient or IgG index are
influenced by the factors listed above, and if they are
influenced, it is possible that the impact would not be
sufficient to affect these measures in a substantial man-
ner. Thus, additional studies are needed to resolve this
potential issue.
In RRMS, there was a trend between decreased CSF
flow and relapse rate in the preceding year [71], and an
elevated albumin quotient at the time of a first clinical
event, thought to be related to MS, is associated with a
greater reduction in volume of several brain structures
within 2 years of the clinical event [62]. This raises the
possibility that the inflammation accounting for this ele-
vation in CSF albumin (or reduced CSF flow), or the
leaked albumin or other plasma component entering the
brain, caused more severe pathological changes.
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Protective roles of albumin during MS
Numerous studies have established that reactive oxygen
species (ROS) and reactive nitrogen species (RNS) are
participants in EAE and MS pathogenesis. Elevation of
markers of ROS and RNS presence have been observed
in leukocytes, serum, CSF, and CNS tissue of EAE and
MS subjects [40, 87–99]. Given the high concentration
of albumin in plasma, and the leakage of the BBB that
occurs during disease, albumin would be expected to be
an abundant substrate for ROS and RNS in MS. Thus,
albumin could have a protective effect on the disease
course by acting as a target for reactive molecules that
otherwise would have greater access to damage more
important biomolecules.
Serum albumin has anti-oxidant properties, in particu-
lar, Cys34 (which is conserved among mammals) scav-
enges free radicals, and six methionine residues can
become oxidized [15, 100]. Besides oxidation, human
serum albumin is a recipient of nitration and nitrosyla-
tion reactions [15, 100–102], and S-nitrosylated human
serum albumin can serve as a transport mechanism for
nitric oxide [103, 104]. Since nitric oxide, i.e., generated
from iNOS, may have a pathogenic role in MS [105], it
is possible that the transportation of nitric oxide by al-
bumin could be beneficial or deleterious depending on
whether it was being removed or delivered, respectively.
Albumin also binds metals and heme. Included among
the metals that bind albumin are copper [106] and iron
[107]. These metals, and heme, can catalyze the forma-
tion of hydroxyl radical, but less so when bound to albu-
min, and the hydroxyl radical catalyzed from a metal
bound to albumin is thought to largely interact with al-
bumin itself rather than damaging other biologically
relevant molecules [14, 15] (Fig. 1). Iron and heme can
also catalyze the nitration of proteins [108–110], but
when heme is bound to human serum albumin [103,
111–114] it may facilitate the detoxification of ROS and
RNS [115–118]. The Cys34 on albumin can also form
disulfide interactions with glutathione, cysteine, or
homocysteine, while Arg410 and Lys525 are main tar-
gets of glycation [15, 119] (discussed below).
Iron and hemoglobin (e.g., extravasated RBCs) have
been detected around damaged vessels in EAE and MS
tissue [28, 32, 33, 40, 98, 120–122] (Fig. 1). This is also
where extravasation of albumin originates thereby result-
ing in a high concentration at this site in comparison to
albumin diffusing away from leaky vessels to other CNS
structures and becoming diluted in the process (Fig. 1).
Since iron and heme can catalyze reactions leading to
oxidation and nitration [108–110, 123–125], it indicates
that albumin is positioned to be an early recipient of
these reactive species during BBB leakage (Fig. 1). Inter-
estingly, nitrated proteins have been detected around
vessels in EAE and MS [40, 126–128], and it has been
put forth that extravasated albumin from leaky vessels is a
main target for nitration during disease [40]. In addition,
extravasated albumin is positioned to directly bind iron
and heme originating from extravasated RBCs or liberated
as a consequence of ongoing tissue damage, e.g., demye-
lination since iron can be abundant within myelin [129]
(Fig. 1). This interaction with albumin would serve to limit
the ability of iron and heme to form toxic radicals [14, 15],
and act to possibly detoxify ROS and RNS [115–117]. The
intravenous administration of albumin to rats with sub-
arachnoid hemorrhage, modeled via endovascular perfor-
ation, resulted in improved behavioral outcomes and
limited BBB leakage, and one mechanism for this effect
could be the binding of heme and/or iron to albumin
thereby limiting ROS and RNS damage [130].
Fig. 1 Protective mechanisms by albumin in the CNS during active
MS disease. a As a consequence of BBB damage, albumin (light blue
dots) becomes extravasated and micro-hemorrhages (RBCs, rust
color) can occur around vessels (royal blue) in MS CNS tissue. The
RBCs breakdown (rust color with black spots) and heme/iron is released
which can catalyze oxidation and nitration reactions. Albumin can bind
heme and iron, which limits their ability to promote tissue damage. In
addition, albumin is often the recipient of toxic species that are
generated (pink dots – oxidized albumin; green dots – nitrated al-
bumin), thereby protecting other CNS biomolecules. Albumin
bound to heme may also detoxify ROS and RNS. b Inflammatory
cells cross the BBB, and can be a source of ROS and RNS, particularly
macrophages (e.g., M1 macrophages) (purple cells). The colocalization
of albumin with macrophages positions albumin to be a target of ROS
and RNS. c Besides macrophages, microglia that become activated dur-
ing MS (yellow cell) can be a source of ROS and RNS. Extravasated albu-
min becomes a target for these toxic species and thereby limiting
tissue damage to other important molecules in the CNS. d Myelin is a
site of iron concentration, and during demyelination (black line frag-
ments) iron is released. This iron can catalyze oxidation and nitration re-
actions together with inflammatory cells, e.g., macrophages. Albumin
can be a recipient of reactive molecules and becomes modified.
Note, the concentration of albumin would become diluted (top left to
lower right) in relation to the distance from the site of the damaged
(leaky) BBB, at least until an equilibrium is reached
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Inflammatory cells, i.e., macrophages and reactive
microglia, can also produce RNS and ROS during EAE
and MS [88, 131–135]. Given that macrophages are a
main participant in active lesions [53–55, 136], extrava-
sated albumin could be a partial buffer limiting the
spread of damage induced by these RNS and ROS to the
surrounding tissue (Fig. 1). Analogously, myeloperoxi-
dase has an elevated expression in macrophages and
microglia in MS and it is thought to promote tissue
damage [133, 137–139]. Since myeloperoxidase causes
oxidation, nitration and nitrosylation to human serum
albumin [140], it raises the possibility that albumin ab-
sorbs some of the toxic products of myeloperoxidase
and thereby protecting more important biomolecules
(Fig. 1).
In CSF from MS subjects, albumin becomes modified
[141] and albumin fragments become carbonylated
(which is thought to result from oxidative stress) [142].
Furthermore, ischemia modified albumin (IMA), which
is thought to result from ROS-induced changes to the
N-terminus of albumin [143], and the IMA/albumin ra-
tio are elevated in sera of patients with stable RRMS
compared to control subjects [144].
Elevated levels of homocysteine have been associated
with vascular injury and atrophy (or neurodegeneration)
of some CNS structures [145, 146], and homocysteine
and cysteine plasma levels are elevated in MS [147-149].
Albumin can regulate thiol/disulfide exchange reactions
in plasma, and albumin is the main protein that binds
homocysteine in plasma [147, 150, 151]. It has been put
forth that homocysteine might promote toxicity to the
CNS [146]; if so, then albumin could influence this
process. For instance, the concentration of homocysteine
is much greater in plasma than CSF [146]; thus, albumin
might act as a carrier delivering homocysteine to the
CNS at times of BBB leakage in MS and potentially
worsening pathology. On the other hand, the binding
homocysteine to albumin, and the rapid clearance of al-
bumin from the CNS, e.g., in active lesions (discussed
above), could limit the ability of homocysteine to pro-
mote toxicity.
The putative synthesis of albumin by microglia
Besides accessing the CNS following BBB leakage, albu-
min may be produced within the CNS. An in vitro and
tissue study found that human microglia produce albumin
and the expression increases upon microglial activation
[152]. Albumin induction in the CNS was also observed
following ischemia [153, 154]. Albumin produced by
microglia was postulated to have a protective role in
Alzheimer’s disease by blocking the polymerization of
amyloid beta and facilitating its clearance [152], and albu-
min produced in the CNS could have additional protective
properties equivalent to those discussed above. However,
in follow up studies, albumin that has become glycated
was shown to be produced by rat and/or human micro-
glial cells that were treated with amyloid beta or ethanol,
and glycated albumin was suggested to promote neurode-
generation [155, 156]. It is not known if glycated albumin
is produced by microglial cells in MS. An elevation of gly-
cated products has been observed in MS tissue [157, 158],
but it is not clear if albumin was among the products, or if
glycated products came from extravasation through a
leaky BBB or were produced endogenously, e.g., in micro-
glia. When albumin becomes glycated it diminishes its
anti-oxidant properties [159–161], and in vitro studies
found that exposure of rat retinal microglial cells to gly-
cated albumin resulted in microglial production of proin-
flammatory cytokines, TNFα and IL-1β [162]. The
expression of these cytokines is increased in MS [163] and
may contribute to MS pathology including enhancing
leakage of the BBB [136, 164]. Thus, glycated albumin
might be in a position to worsen disease activity in MS, al-
though it is unclear what the outcome would be if other
molecules became glycated in place of albumin.
In contrast to glycated albumin, production of non-
glycated albumin in the CNS is likely protective. How-
ever, it is still unclear whether albumin is produced by
CNS cells in MS. In one study, albumin was detected
within astrocytes, oligodendrocytes, axons, and macro-
phages in inactive plaques [7], which would support in
situ synthesis, but additional studies are warranted, es-
pecially on active plaques, in order to fully establish
which cells, if any, produce albumin in MS. Further-
more, even if albumin is synthesized in the CNS, it is
unclear whether the amount produced will be suffi-
cient to substantially influence albumin levels in the
CSF or albumin levels in the CNS resulting from a
breach in the BBB.
Albumin as a therapy in models of CNS diseases
Albumin administered in high doses has been examined
for therapeutic value in models of some CNS diseases.
In models of ischemia (e.g., global, transient focal, or
permanent focal) or traumatic brain injury, administra-
tion of albumin resulted in protection, e.g., reduced in-
farction volume [165, 166]. Most of the benefits are
thought to be related to hemodynamics effects, such as
expanding the volume of the blood, but other mecha-
nisms (similar to those discussed above) could also have
protective roles [165]. In addition, the binding of albu-
min to megalin, a receptor on astrocytes [167], stimu-
lates cultured astrocytes to produce oleic acid, which
might support neuronal differentiation during develop-
ment [168, 169]. Albumin also binds oleic acid [170],
and treatment with albumin or albumin-oleic acid pro-
moted recovery [171, 172] and decreased microglial
activation [172] following spinal cord injury in the rat.
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Although it is possible that administration of exogen-
ous albumin or albumin-oleic acid may confer some
benefits for MS similar to the preclinical results de-
scribed above for other conditions, high dose albumin
therapy has been tested in clinical trials for ischemic
stroke but was found to have no benefit, and it even in-
creased mortality in subjects that were > 83 years old
[173]. The increased mortality in elderly individuals was
suggested to be due to increased myocardial stress
[174]; of note, there is evidence to suggest that MS pa-
tients have a greater risk for myocardial infarction
[175]. Thus, great caution should be taken before pursu-
ing a similar strategy in MS even if pre-clinical studies
provide encouraging results.
Possible pathogenic roles of albumin during MS
Some studies obtained results suggesting that albumin
has the potential to worsen disease activity in the CNS.
For instance, injection of albumin into the neostriatum
in one hemisphere resulted in a greater lesion volume
compared to injection of saline into the other hemi-
sphere in the rat [176] while infusion of serum or serum
fraction(s) in CA1 sector or striatum led to neuronal loss
or inflammatory lesions in these respective locations
[177]. However, the outcomes observed in these studies
could have been due to factors other than the injected
albumin or serum components. For instance, the os-
motic effects of albumin or serum proteins, and/or the
large volume of injected material may account for the le-
sions since a slow injection of plasma proteins into the
hippocampus did not cause neurodegeneration [178]. In
another study, an intracerebroventricular injection of al-
bumin didn’t result in neurodegeneration in rats, however,
when it was combined with hippocampal administration
of kainic acid, which is used to induce seizures, neurode-
generation of CA3 neurons was enhanced compared to
kainic acid plus vehicle [179].
Seizure activity is associated with an opening of the
BBB, and extravasation of albumin into the brain is
thought to increase the excitability of neurons and in-
duce proinflammatory events. For example, a model of
status epilepticus in rats resulted in extravasation of al-
bumin in the hippocampus, which was diffusely distrib-
uted at 2 h post status epilepticus and became
concentrated in CA3 neurons at 24 h [179]. An intra-
cerebroventricular injection of albumin resulted in high
frequency, high amplitude spiking activity in the rat
hippocampus lasting 1 h after injection, and induced IL-
1β expression by hippocampal astrocytes at 2 h, which
was further increased by 24 h [179]. Besides induction
in astrocytes, albumin can induce microglia to express
IL-1β [180]. In studies involving CSF from MS patients
with active disease, together with in vitro mouse brain
slice preparations and other related analyses, IL-1β was
found to be associated with inducing excitatory postsyn-
aptic currents and glutamate excitotoxic neuronal dam-
age [181]. Albumin can also induce other inflammatory
responses by astrocytes and microglia. For example, al-
bumin can induce astrocytic expression of CX3CL1
[180], which is a chemokine involved in CNS recruit-
ment of CD4+ T cells in RRMS [182], and albumin can
induce microglial activation, i.e., increase intracellular
levels of calcium and proliferation [183]. Albumin can
also induce astroglial and microglial expression of nitric
oxide metabolites [180].
Both the prevalence and incidence of seizure disor-
ders is greater in MS patients than in the general
population [184], but even without seizures, it is pos-
sible that leakage of albumin through a damaged BBB
in MS could lead to some similar pathogenic events
that occur in epilepsy. Epilepsy results in BBB leakage
and extravasation of albumin into CNS structures, and
the presence of albumin is thought to exacerbate
disease by inducing inflammatory events (discussed
above) and by altering potassium homeostasis [76]. In
the CNS, extravasated or exogenously administered
albumin results in its presence in the parenchyma and
uptake by microglia, astrocytes and neurons [73–76]
leading to astrocyte gliosis and neuronal loss [185].
Mechanistically, albumin is thought to enter astro-
cytes after interacting with TGF-β receptors and this
uptake affects calcium concentrations in the cyto-
plasm [186] and results in the downregulation of
Kir4.1 in astrocytes [73, 76, 179]. Extracellular potas-
sium homeostasis becomes disrupted [73, 187] and
neurons may become hyper-excitable to NMDA re-
ceptor activation [73, 76]. Also, albumin in neurons
can increase the synthesis of glutamate [188] further-
ing this cycle. Since glutamate has been implicated in
neurodegeneration in MS [189], it suggests that albu-
min could amplify pathology via this mechanism in-
volving disruption of potassium homeostasis leading
to greater sensitivity to glutamate.
Kir4.1 is localized to oligodendrocytes, perivascular
astrocytes, astrocyte endfeet, and astrocyte processes
associated with synapses [190, 191]. Interestingly,
autoantibodies to Kir4.1 are at higher levels in MS than
in controls, and are increased during a disease relapse
compared to remission [192, 193], but their presence
and/or role in MS have been questioned [194–196].
The expression of Kir4.1 is altered in MS lesions; in
acute or chronic active demyelinating lesions Kir4.1
levels decreased while periplaque reactive astrocytes
had increased levels [191]. Similar to its actions in
epilepsy, it is possible that extravasated albumin can
influence Kir4.1 expression in MS, and further dysreg-
ulation of Kir4.1 expression could facilitate the neuro-
degenerative process.
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Conclusions
In MS, CNS cells can become bathed by albumin in the
context of ongoing inflammation following BBB disrup-
tion. Although many functions have been attributed to
albumin, its role in MS has received little attention.
Damage to the BBB in MS is relatively common, and
given the high concentration of albumin in plasma, it
readily passes from the circulation into the CNS during
BBB leakage. Although the albumin quotient is used as
an indication of blood-CSF dysfunction, many factors
can influence the CSF concentration of albumin indicat-
ing that this measurement is an imprecise indicator of
BBB leakage or blood-CSF dysfunction. Once albumin
becomes extravasated into the CNS, it can exert benefi-
cial and/or harmful effects. Beneficial actions include al-
bumin being a target for ROS and RNS, and in so doing
limiting damage to other molecules. Albumin can also
reduce the production of ROS and RNS by binding iron
and heme. Despite these protective properties, albumin
may promote pathology by acting to induce the produc-
tion of proinflammatory cytokines, or disrupting potas-
sium homeostasis making neurons potentially more
vulnerable to glutamate excitotoxicity. Given the abun-
dance of albumin together with frequent disruptions to
the BBB, further studies are warranted to advance the
understanding of the impact that albumin has on cellular
functions and pathogenic processes in the context of
MS. Some other pertinent areas of research include in-
vestigations on the roles of albumin variants, modified
albumin (e.g., glycated albumin), and albumin levels on
the disease course. Additionally, detailing the role of al-
bumin in relation to the delivery or action of disease
modifying therapies, and other drugs that are used to
treat MS patients, is of interest.
In summary, given that albumin represents such a
large percentage of the proteins that become extrava-
sated during BBB leakage, albumin likely performs a
multitude of roles that are largely dependent on the
microenvironment albumin becomes exposed to during
disease.
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